Tenth Circuit Finds Citizen Petition Denial to be "Clear Evidence" of Conflict Preemption

by Shook, Hardy & Bacon L.L.P.

Shook, Hardy & Bacon L.L.P.

A U.S. Court of Appeals has held that a Food and Drug Administration (FDA) denial of a citizen petition can be “clear evidence” of conflict preemption under the test set forth by the Supreme Court in Wyeth v. Levine, 555 U.S. 555 (2009).

At issue in Cerveny v. Aventis was whether Aventis failed to warn the plaintiffs of the risk of using fertility drug Clomid to become pregnant. Victoria Cerveny took Clomid in October 1992, before her pregnancy; Alexander Cerveny was born in July 1993 with a deformity of his left elbow and only three digits on his left hand. The complaint alleged that Clomid causes birth defects in women who take it before pregnancy, in part because it has a long half-life and can remain in a woman’s blood into the second month of pregnancy.

When Clomid entered the U.S. market in 1967, its label contained a warning that “inadvertent” use of the drug during early stages of pregnancy had resulted in fetal harm in animal testing but that there was no causative evidence of risk in humans. In the mid- to late-1980s, FDA and Aventis drafted possible changes to the prescribing information accompanying Clomid that dealt primarily with the risk to women who took Clomid during pregnancy. Aventis eventually made some changes to the label, but not until after Alexander Cerveny was born. The plaintiffs claimed that had FDA’s suggested warning been on the label in 1992, Victoria Cerveny never would have taken the drug.

In 2007, a California attorney who had filed several Clomid lawsuits alleging that use of the drug before pregnancy caused birth defects submitted a citizen petition to FDA urging that the drug’s label be changed to include a warning about the teratogenic risks of the drug if it was used before pregnancy. The petition claimed that Clomid’s long half-life caused it to be “biologically active well into the second month of pregnancy” and asserted that the drug caused, among other things, congenital musculoskeletal abnormalities. FDA rejected the petition in 2009 and, after it was re-submitted, again in 2012. As Shook attorneys argued to the trial and appeals courts, FDA considered the available scientific evidence and “twice unequivocally” determined that it did not meet the regulatory standard for adding a warning. Specifically, FDA decided that the “currently available, relevant and reliable scientific evidence” did not establish that the use of Clomid before pregnancy carried teratogenic risks.

Shook attorneys moved for summary judgment on the plaintiffs’ five claims: failure to warn (strict liability); failure to warn (negligence); breach of implied warranty; negligent misrepresentation; and fraud. They argued to the Utah trial court that the claims were preempted because FDA’s rejection of the citizen petition constituted “clear evidence” that the agency would not have approved the warning that Clomid carried a risk of fetal harm if taken before pregnancy. The trial court agreed and granted Shook’s motion for all five claims.

The plaintiffs appealed, arguing that the trial court applied the Wyeth “clear evidence” test too broadly and that FDA rejection of a citizen petition, standing alone, could not be clear evidence that FDA would have rejected a manufacturer’s request to change a label under the agency’s Change Being Effected (CBE) regulation. Shook attorneys, along with amici Pharmaceutical Research and Manufacturers of America and the Biotechnology Innovation Organization, argued that FDA applies the same level of scrutiny and the same standard to changes in warning labels whether the request for change comes from a manufacturer or through a citizen petition. In addition, amici U.S. Chamber of Commerce, American Tort Reform Association and National Association of Manufacturers joined Shook’s argument that FDA regulations allow a manufacturer to change a drug label only if there is “reasonable” evidence of a causal relationship between the drug and the alleged risk.

Although the Tenth Circuit reversed and remanded some of the plaintiffs’ claims with instructions for the district court to reconsider its rulings on those, the appellate court came down squarely on the drug manufacturer’s side on the main issue. Ruling that FDA’s denial of the citizen petition was “clear evidence” on its own that the agency would not have approved a request from Aventis to add a pre-pregnancy warning label for Clomid, the Tenth Circuit upheld summary judgment on the failure-to-warn claims. The court said:

Under the same standard for manufacturer-initiated changes, the FDA rejected a citizen petition containing arguments virtually identical to the Cervenys’. We will not assume that the FDA would have scuttled its own regulatory standard if Aventis had requested the new warning.

The holding clarifies the “clear evidence” standard considered in Wyeth and provides new guidance for pharmaceutical manufacturers facing liability claims—but it does not benefit only those who can point to a relevant citizen petition. The holding rejects arguments that plaintiffs have successfully advanced in other districts courts: namely, (i) that citizens’ petitions alone can never be preemptive; and (ii) that only FDA’s denial of a manufacturer’s proposed label change can meet the “clear evidence” standard of Wyeth. This opinion should help other manufacturers faced with state-law claims that should be preempted under the Supreme Court’s opinion in Wyeth.

Cerveny v. Aventis, No. 16-4050 (10th Cir., May 2, 2017).

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Shook, Hardy & Bacon L.L.P. | Attorney Advertising

Written by:

Shook, Hardy & Bacon L.L.P.

Shook, Hardy & Bacon L.L.P. on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.